18 years survival following CAR T cell therapy to treat neuroblastoma
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy. The findings, published in Nature Medicine, describe several long-term survivors in a follow-up from a phase 1 clinical trial